1. Introduction {#sec1-cancers-12-01850}
===============

Axl, also known as UFO, belongs in the Tyro3, MerTK, and Axl (TAM) subfamily of receptor tyrosine kinases. Axl and other TAM receptors can be activated via their ligands, growth arrest specific 6 protein (Gas6) and Protein S (Pros1), which are members of the family of vitamin K-dependent proteins. Axl is overexpressed in many cancer types and is associated with therapeutic resistance, poor clinical prognosis, and worse outcome \[[@B1-cancers-12-01850],[@B2-cancers-12-01850],[@B3-cancers-12-01850],[@B4-cancers-12-01850]\]. Pre-clinical studies of Axl indicate that Axl mediates key components of the metastatic cascade, including but not limited to epithelial-to-mesenchymal transition, migration and invasion, proliferation, survival, stemness, and angiogenesis. In addition, soluble Axl (sAXL), an 80--85 kDa protein, is produced by the proteolytic cleavage of extracellular domains by A Disintegrin and Metalloproteinases 10 and 17 \[[@B5-cancers-12-01850],[@B6-cancers-12-01850]\]. Increased serum levels of sAXL are associated with disease progression in a number of cancer types \[[@B4-cancers-12-01850],[@B7-cancers-12-01850],[@B8-cancers-12-01850]\]. While the role of Gas6 and Axl in cancer has been broadly reviewed elsewhere \[[@B9-cancers-12-01850],[@B10-cancers-12-01850]\], it is becoming increasingly clear that this signaling axis also impacts non-neoplastic cell populations which may be of particular interest when viewed in the context of the tumor microenvironment.

The importance of the tumor microenvironment in cancer development, progression, metastasis, and therapeutic resistance is now well recognized \[[@B11-cancers-12-01850]\]. Furthermore, the tumor immune microenvironment (TIME) has gained significant attention over the last several decades, as neoplastic cells are able to promote the immunosuppressive microenvironment and evade immune surveillance. Indeed, the composition of the immune cells in the tumor microenvironment may predict clinical prognosis, therapeutic efficacy, and disease outcome \[[@B12-cancers-12-01850]\]. An emerging factor in the modulation of the TIME is the Gas6/Axl signaling axis. This review focuses on the role of Gas6/Axl signaling in the tumor microenvironment, and its relation to potential mechanisms of immune evasion.

2. The Gas6/Axl Signaling Pathway {#sec2-cancers-12-01850}
=================================

AXL was first isolated from chronic myelogenous leukemia cells in 1988 \[[@B13-cancers-12-01850]\] and characterized in 1991 \[[@B14-cancers-12-01850],[@B15-cancers-12-01850]\]. Like all TAM receptors, Axl is composed of two immunoglobulin-like (IgL) domains, two fibronectin III (FNIII) domains, a transmembrane domain, and an intracellular kinase domain \[[@B15-cancers-12-01850]\] ([Figure 1](#cancers-12-01850-f001){ref-type="fig"}A). The Axl protein contains 894 amino acids with a glycine-rich loop (Gly^543^- Gly^548^), a catalytic loop (His^670^-Asn^677^), and a DFG motif (Asp^690^-Phe^691^-Gly^692^). Although the molecular weight of the full-length Axl is 104 kDa, post-translational modifications of the extracellular domains give rise to two modified forms with molecular weights 120 and 140 kDa. Potential N-linked glycosylation sites include Asn^43^, Asn^157^, Asn^198^, Asn^339^, Asn^345^, and Asn^401^ \[[@B15-cancers-12-01850]\].

Gas6 is one of the ligands for TAM receptors, with the highest affinity for Axl compared to Tyro3 or MerTK \[[@B16-cancers-12-01850]\]. Gas6 was first identified by Schneider and colleagues in 1988 \[[@B17-cancers-12-01850]\], and was characterized to be abundantly expressed in serum-starved 3T3 cells \[[@B17-cancers-12-01850],[@B18-cancers-12-01850]\]. Gas6 contains 678 amino acids, with gamma-carboxyglutamic acid (Gla) domains (amino acids 49--90), four epidermal growth factor (EGF)-like domains (amino acids 118--278), and two laminin G-like (LG) domains (amino acids 279--678) \[[@B18-cancers-12-01850],[@B19-cancers-12-01850]\] ([Figure 1](#cancers-12-01850-f001){ref-type="fig"}A). The N-terminus Gla domain mediates binding to cell membranes, particularly phosphatidylserine, in a calcium-dependent mechanism \[[@B20-cancers-12-01850],[@B21-cancers-12-01850]\]. The crystal structures of Axl and Gas6 complex revealed that the C-terminus LG1 domain of Gas6 binds to the IgL-1 and IgL-2 domains of Axl \[[@B22-cancers-12-01850],[@B23-cancers-12-01850]\]. Upon Gas6--Axl interaction, the complex dimerizes with another Gas6--Axl complex to form a 2:2 homodimerized complex with no direct Axl/Axl or Gas6/Gas6 contacts \[[@B22-cancers-12-01850]\]. In addition, Axl has been reported to heterodimerize with other receptor tyrosine kinases, including EGFR \[[@B24-cancers-12-01850],[@B25-cancers-12-01850]\], HER2 \[[@B26-cancers-12-01850]\], HER3 \[[@B24-cancers-12-01850]\], c-Met \[[@B27-cancers-12-01850]\], and Tyro3 \[[@B28-cancers-12-01850]\].

In the intracellular kinase domain of human Axl, tyrosine residues Tyr^698^, Tyr^702^, and Tyr^703^ are conserved among the TAM receptors. In addition, tyrosine residues (Tyr^779^, Tyr^821^, and Tyr^866^) interact with a number of signaling molecules, including phospholipase C (PLC), phosphatidyl inositol 3 kinase (PI3K), and Grb2 \[[@B29-cancers-12-01850],[@B30-cancers-12-01850]\], and have been proposed as potential sites of autophosphorylation \[[@B15-cancers-12-01850],[@B29-cancers-12-01850]\]. However, these conclusions must be viewed with caution as many of the earlier signaling studies used a chimeric EGFR/Axl receptor and both extracellular and intracellular domains impact the downstream signaling pathways \[[@B31-cancers-12-01850],[@B32-cancers-12-01850]\]. Studies have demonstrated that genetic and pharmacologic inhibitions of Axl affect downstream signaling pathways including JAK-STAT, PI3K-AKT, and RAS-RAF-MEK-ERK \[[@B33-cancers-12-01850],[@B34-cancers-12-01850]\].

3. GAS6 and AXL Expression in the Tumor Microenvironment {#sec3-cancers-12-01850}
========================================================

The tumor microenvironment consists of abnormal physiologic conditions, secreted factors, and host tumor-supporting cells, all of which play essential roles in cancer progression and metastasis \[[@B35-cancers-12-01850]\]. While Axl expression on neoplastic cells is readily recognized, it is less well known that Axl is expressed by a variety of host cells found in the tumor microenvironment, including several immune cell types \[[@B36-cancers-12-01850]\], fibroblasts \[[@B37-cancers-12-01850]\], osteoclasts \[[@B38-cancers-12-01850]\], and endothelial cells \[[@B39-cancers-12-01850],[@B40-cancers-12-01850],[@B41-cancers-12-01850]\] ([Figure 1](#cancers-12-01850-f001){ref-type="fig"}B,C). Furthermore, the unique tumor microenvironmental conditions may modulate Axl and Gas6 expression in both neoplastic and host cells to promote aggressive and pro-tumorigenic phenotypes. For example, abnormal physiologic conditions such as low oxygen levels, or hypoxia, are a common occurrence in solid tumors and are known to be negative prognostic factors associated with disease progression and poor outcome \[[@B42-cancers-12-01850]\]. Hypoxia upregulates hypoxia inducible factor-1 and -2 (HIF-1 and HIF-2), and modulates the expression of genes associated with angiogenesis, metabolism, cell survival, proliferation, motility, and invasiveness \[[@B43-cancers-12-01850]\]. Several studies demonstrated that hypoxia upregulates and stabilizes Axl \[[@B4-cancers-12-01850],[@B44-cancers-12-01850],[@B45-cancers-12-01850]\]. In addition to hypoxia, cytokines including transforming growth factor beta (TGF𝛽), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon-alpha (IFN⍺), have been shown to induce Axl expression \[[@B6-cancers-12-01850],[@B46-cancers-12-01850]\]. Hence, the tumor microenvironment can modulate Axl expression in the various cell populations comprising tumors, to the point that Axl may be a critical mediator of the multimodal roles associated with tumor development, progression and metastasis

3.1. Axl Expression in Host Cells {#sec3dot1-cancers-12-01850}
---------------------------------

Axl expression on endothelial cells is involved in mediating normal and tumor vasculature. For example, Axl inhibition decreases Tie2 and VEGFR-2 expression and impairs VEGF-A and lactate-induced activation of Akt \[[@B47-cancers-12-01850],[@B48-cancers-12-01850]\]. In addition, Axl inhibition in tumor-bearing mice impairs tumor cell-induced angiogenesis and decreases immunohistochemical staining of the endothelial cell marker CD31 in the tumor \[[@B49-cancers-12-01850],[@B50-cancers-12-01850],[@B51-cancers-12-01850],[@B52-cancers-12-01850]\]. Therefore, Axl inhibition impairs tumor cell-induced angiogenesis.

Axl expression on the cells of the human and murine immune system have been reviewed previously \[[@B53-cancers-12-01850]\] ([Figure 1](#cancers-12-01850-f001){ref-type="fig"}C). Axl is primarily expressed by myeloid-lineage cells to phagocytose apoptotic cells and debris. Broadly, Axl is expressed on bone marrow derived cells (BMDCs) \[[@B54-cancers-12-01850],[@B55-cancers-12-01850],[@B56-cancers-12-01850],[@B57-cancers-12-01850]\], dendritic cells (DCs) \[[@B6-cancers-12-01850],[@B36-cancers-12-01850],[@B58-cancers-12-01850],[@B59-cancers-12-01850]\], macrophages \[[@B60-cancers-12-01850],[@B61-cancers-12-01850]\], monocytes \[[@B56-cancers-12-01850]\], natural killer (NK) cells \[[@B62-cancers-12-01850]\], and platelets \[[@B63-cancers-12-01850]\]. In addition, neoplastic cells may induce the expression of Axl and Gas6 in monocytic myeloid derived suppressor cells (M-MDSCs) and polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) \[[@B64-cancers-12-01850]\]. Hence, the interactions between the neoplastic and host immune cells in the tumor microenvironment can potentiate the expression of Axl and Gas6 to promote a pro-tumorigenic microenvironment.

3.2. Gas6 Expression in Host Cells {#sec3dot2-cancers-12-01850}
----------------------------------

In addition to neoplastic cells, Gas6 is expressed by luminal progenitor and basal cells around the ductal lining of the mammary tissue \[[@B65-cancers-12-01850]\]. In the bone microenvironment, Gas6 is secreted by osteoblasts that are involved in forming bones \[[@B66-cancers-12-01850],[@B67-cancers-12-01850],[@B68-cancers-12-01850]\]. Khoo and colleagues demonstrated that osteoblast-derived Gas6 induced Axl expression on neoplastic cells \[[@B68-cancers-12-01850]\], suggesting that paracrine Gas6/Axl signaling promotes survival, inhibits apoptosis, and mediates homing of tumor cells to the bone.

In the tumor microenvironment, cancer-associated fibroblasts (CAFs) and CD45^+^-expressing tumor-infiltrating leukocytes (TILs) also express Gas6 \[[@B69-cancers-12-01850],[@B70-cancers-12-01850],[@B71-cancers-12-01850],[@B72-cancers-12-01850]\]. Among the TILs, macrophages and dendritic cells express high levels of Gas6 \[[@B71-cancers-12-01850],[@B72-cancers-12-01850]\], which can be further promoted in these cell types by IL-10, M-CSF, and IFN⍺ \[[@B6-cancers-12-01850],[@B72-cancers-12-01850]\]. CD45^+^ cells from the bone marrow or the peripheral blood express significantly less Gas6 than TILs \[[@B72-cancers-12-01850]\]. Although the mechanisms underlying Gas6 upregulation in TILs is not fully understood, in vitro studies demonstrate that tumor cells or tumor cell conditioned media induce Gas6 expression and secretion in macrophages \[[@B71-cancers-12-01850],[@B73-cancers-12-01850]\]. Gomes and colleagues showed that stromal cell-derived Gas6 promotes tumor cell migration, invasion, survival, and proliferation \[[@B70-cancers-12-01850],[@B71-cancers-12-01850]\]. Potential downstream effectors of the Gas6/Axl signaling through macrophage-derived Gas6 include pAkt and pStat3 \[[@B64-cancers-12-01850],[@B71-cancers-12-01850]\]. In vivo, colorectal CT26 tumors grew slower in Gas6^−/−^ mice compared to wild-type (WT) mice \[[@B72-cancers-12-01850]\]. In this model, transplanting bone marrow derived from Gas6^−/−^ mice into WT mice resulted in the slowing of tumor growth, suggesting that Gas6 from BMDCs supports tumor growth \[[@B72-cancers-12-01850]\].

4. Mechanisms of Axl-Mediated Tumor Immune Response {#sec4-cancers-12-01850}
===================================================

The immune system plays an important role in cancer development, progression and metastasis \[[@B12-cancers-12-01850]\], and it is becoming clear that both tumor intrinsic and extrinsic factors modulate the composition of the TIME \[[@B74-cancers-12-01850],[@B75-cancers-12-01850]\]. Neoplastic cells alter the expression of cell surface molecules to avoid detection by surveilling immune cells. As such, a number of studies have revealed that Axl mediates key roles in promoting the immune suppressive tumor microenvironment ([Figure 2](#cancers-12-01850-f002){ref-type="fig"}).

4.1. Major Histocompatibility Complex Class I (MHC-I) {#sec4dot1-cancers-12-01850}
-----------------------------------------------------

Major histocompatibility complex class I (MHC-I) molecules are present on the surface of all nucleated cells. When normal cells that are damaged, infected or considered 'foreign', MHC-I presents 8 to 11 amino acid-long epitopes derived from the MHC-I-expressing cell. These antigen-bound MHC-I complexes are recognized by circulating CD8^+^ T-cells and bind to the MHC-I complex by the CD8^+^/T-cell receptor complex. Upon binding, CD8^+^ T-cells are activated and secrete perforin and granzymes to lyse tumor cells. Hence, MHC-I presentation by neoplastic cells and other professional antigen presenting cells (APCs) is important for the eradication of tumor cells. An association between MHC-I and Axl was first observed by Rothlin and colleagues, who demonstrated that TAM knockout mice (Tyro3^−/−^Axl^−/−^MerTK^−/−^) had increased MHC-I-expressing myeloid cells \[[@B36-cancers-12-01850]\]. More recently, studies by Guo and colleagues and Aguilera and colleagues independently showed that pharmacologic inhibition and genetic knockout of Axl, respectively, decreased surface level expression of MHC-I \[[@B76-cancers-12-01850],[@B77-cancers-12-01850]\].

4.2. Programmed Cell Death Ligand 1 (PD-L1) {#sec4dot2-cancers-12-01850}
-------------------------------------------

Neoplastic cells can escape immune surveillance and promote immune evasion through modulating the expression of cell surface receptors and ligands that differentiate between host and foreign cells. When neoplastic cells express immune checkpoint molecules, the host immune system recognizes these cells as 'self' instead of 'foreign', and prevents cell killing. Hence, immune checkpoint pathways have gained significant attention as potential therapeutic targets.

Programmed cell death ligand 1 (PD-L1) is one of the immune checkpoint molecules expressed in a number of tumor cell types. The interaction between PD-L1 with its receptor PD-1 on T-cells potentiates inhibitory signaling pathways to prevent T-cell activation \[[@B78-cancers-12-01850]\]. This way, PD-L1-expressing neoplastic cells avoid immune-mediated cell death and continue to proliferate and survive in the TME (tumor microenvironment). Indeed, pharmacologic Axl inhibition using a selective Axl inhibitor, bemcentinib or BGB324, in lung adenocarcinoma cell lines (PC9 and H1975) significantly decreased PD-L1 and PD-L2, another ligand that binds to PD-1 \[[@B79-cancers-12-01850]\]. Similarly, Axl knockdown in the human triple negative breast cancer cell line (MDA-MB-231) also decreased PD-L1 expression \[[@B80-cancers-12-01850]\].

4.3. Altered Secretome {#sec4dot3-cancers-12-01850}
----------------------

Axl signaling promotes an immune suppressive and pro-tumorigenic microenvironment through altered secretion of cytokines that modulate immune cell trafficking, migration, polarization, and adhesion \[[@B81-cancers-12-01850],[@B82-cancers-12-01850]\] ([Table 1](#cancers-12-01850-t001){ref-type="table"}). For example, a conditioned medium of an Axl knockout breast cancer cell line showed decreased secretion of granulocytic-colony stimulating factor (G-CSF) \[[@B77-cancers-12-01850]\], which is known to promote accumulation of granulocytic-myeloid derived suppressor cells (G-MDSCs) in the TME \[[@B83-cancers-12-01850]\]. Similarly, bemcentinib also decreased G-CSF in a genetically engineered mouse model of pancreatic cancer (Kras^LSL-G12D^; Cdkn2a^fl/fl^; Ptf1a^Cre/+^, KIC) \[[@B84-cancers-12-01850]\]. Other studies have demonstrated that pharmacologic inhibition of Axl decreases IL-4 expression in the tumor \[[@B55-cancers-12-01850],[@B84-cancers-12-01850]\], which promotes tumor progression and metastasis through mediating proliferation and survival of lymphocytes, and macrophage polarization towards the M2-like phenotype \[[@B85-cancers-12-01850]\].

Chemokines are 8 to 10 kDa chemotactic cytokines that signal through seven transmembrane G protein-coupled receptors. Genetic and pharmacologic inhibitions of Axl impair secretion of chemokines involved in recruiting monocytes, macrophages, and M-MDSCs (CCL-2, CCL-3, CCL-4, and CCL-5) \[[@B76-cancers-12-01850],[@B77-cancers-12-01850],[@B84-cancers-12-01850]\], and promote secretion of chemokines involved in recruiting Th1, CD8^+^ T-cells, and NK cells (CXCL9, CXCL10, and CXCL11) \[[@B76-cancers-12-01850]\] ([Figure 2](#cancers-12-01850-f002){ref-type="fig"}).

Such altered cytokine secretion patterns in the tumor microenvironment may be associated with the suppressor of the cytokine signaling (SOCS) pathway. Physiologically, toll-like receptors (TLRs) are involved in innate immunity, particularly among dendritic cells and macrophages, as pattern recognition receptors. Activation of TLRs induces expression and secretion of proinflammatory cytokines. In dendritic cells, TLR activation also upregulates Axl \[[@B36-cancers-12-01850]\]. The upregulated Axl is involved in the negative feedback regulation by forming a complex with a type I interferon receptor (IFNAR). Signaling through Axl--IFNAR induces the expression of the SOCS1 and SOCS3 that inhibit proinflammatory cytokine release and promote immunosuppression to maintain tissue homeostasis \[[@B36-cancers-12-01850],[@B86-cancers-12-01850]\]. Hence, Axl mediates cytokine secretions by IFNAR, SOCS1 and SOCS3, at least in these in vitro immune cell cultures. However, whether these are downstream effectors of Axl signaling in the tumor cells remains unknown.

5. Involvement of the Gas6/Axl Signaling in Immune Cell Recruitment {#sec5-cancers-12-01850}
===================================================================

Since the Gas6/Axl signaling pathway promotes an immunosuppressive TME, it is perhaps not surprising that the recruitment of specific immune cell types and the overall composition of the TIME also are altered ([Figure 2](#cancers-12-01850-f002){ref-type="fig"}). Immune cells can be broadly categorized as myeloid- or lymphoid- lineage cells that are involved in innate and adaptive immune responses, respectively. Both myeloid and lymphoid lineage cells collaborate to destroy foreign pathogens, including cancer cells. Still, tumor cells avoid detection and destruction by a number of immune cells, which is now considered one of the hallmarks of cancer \[[@B74-cancers-12-01850]\].

Myeloid-lineage (CD11b^+^) cells consist of basophils, eosinophils, dendritic cells, mast cells, monocytes, macrophages, myeloid derived suppressor cells, natural killer cells, and neutrophils. Axl knockdown in a glioblastoma cell line decreased the percentage of tumor-infiltrating CD11b^+^ cells \[[@B87-cancers-12-01850]\]. However, this was not observed in a pancreatic cancer model \[[@B84-cancers-12-01850]\] ([Table 2](#cancers-12-01850-t002){ref-type="table"}). Since CD11b^+^ cells represent a large group of cell types, this marker alone cannot predict the inflammatory status of the tumor. Of the CD11b^+^ cells, Guo and colleagues demonstrated that a selective Axl inhibitor, bemcentinib, decreased the number of infiltrating monocytes and macrophages in ID8 and 4T1 tumors \[[@B76-cancers-12-01850]\] ([Table 2](#cancers-12-01850-t002){ref-type="table"}). Similarly, in murine pancreatic cancer models, bemcentinib decreased tumor infiltrating macrophages \[[@B84-cancers-12-01850],[@B88-cancers-12-01850]\].

CD11b^+^ cells found in the tumor immune microenvironment can be a double-edged sword in terms of cancer progression. While the infiltration of myeloid derived suppressor cells and tumor-associated macrophages (TAMs) promotes the immunosuppressive and pro-tumorigenic microenvironment, M1-like macrophages and dendritic cells can stimulate proinflammatory and anti-tumorigenic responses. Of the myeloid lineage cells, dendritic cells and macrophages are professional APCs that help to activate the adaptive immune response. Tumor infiltrating cDCs are thought to engulf dead- or dying- neoplastic cells or their cellular debris, process and present tumor-specific antigens through MHC-I or MHC-II, and mediate the cancer immunity cycle \[[@B89-cancers-12-01850]\].

Lymphoid lineage cells consist of T-cells (thymus-derived), B-cells (bone marrow-derived), and natural killer T (NKT) cells. In particular, T-cells can be broadly categorized into CD8^+^ T-cells and CD4^+^ T-cells that recognize MHC-I and MHC-II on APCs, respectively. Hence, cells of the innate and adaptive immune system must work together to destroy neoplastic cells. Indeed, studies demonstrate that pharmacologic and genetic inhibitions of Axl increased the number of tumor-infiltrating cDCs \[[@B55-cancers-12-01850],[@B76-cancers-12-01850],[@B77-cancers-12-01850],[@B84-cancers-12-01850]\] and the number of tumor-infiltrating CD4^+^ T-cells \[[@B55-cancers-12-01850],[@B76-cancers-12-01850],[@B77-cancers-12-01850]\] ([Table 2](#cancers-12-01850-t002){ref-type="table"}).

Among cDCs, CD103^+^ cDCs, but not CD11b^+^ cDCs, transport tumor-derived antigens to the tumor-draining lymph nodes and prime CD8^+^ T-cells for tumor cell lysis \[[@B90-cancers-12-01850],[@B91-cancers-12-01850]\]. Guo and colleagues showed that bemcentinib-treated tumors increased CD103^+^ cDCs but not CD11b^+^ cDCs \[[@B76-cancers-12-01850]\]. One study demonstrated that Axl inhibition increases the number of tumor-infiltrating CD8^+^ T-cells \[[@B92-cancers-12-01850]\], while other studies demonstrated that Axl inhibition has no effect on the number of tumor-infiltrating CD8^+^ T-cells \[[@B55-cancers-12-01850],[@B77-cancers-12-01850],[@B87-cancers-12-01850]\] ([Table 2](#cancers-12-01850-t002){ref-type="table"}). Hence, further studies are warranted to understand the role of the Gas6/Axl signaling in the cancer immunity cycle.

6. Conclusions {#sec6-cancers-12-01850}
==============

The Gas6/Axl signaling pathway in neoplastic cells mediates multiple aspects of tumor progression and metastasis, including tumor cell proliferation, migration, invasion, survival, angiogenesis, therapeutic resistance, and immune evasion. Axl has been shown to be overexpressed in many cancer types, and is associated with poor clinical prognosis and outcome \[[@B9-cancers-12-01850]\].

Yet, the tumor microenvironment consists of not only neoplastic cells, but also multiple normal host cell types that can support tumor growth, survival and metastasis. Crosstalk between neoplastic cells and immune cells can promote an immunosuppressive tumor microenvironment and immune evasion, which is considered one of the hallmarks of cancer \[[@B74-cancers-12-01850]\]. These immune cells mediate tumor development, progression, and metastasis. Hence, the composition of the TIME may predict clinical prognosis, therapeutic efficacy, and disease outcome \[[@B12-cancers-12-01850]\]. Indeed, the Gas6/Axl signaling pathway has been implicated in the promotion of the immunosuppressive tumor microenvironment and immune evasion through (1) altering surface level expression of MHC-I and PD-L1, (2) promoting secretion of immunosuppressive cytokines, and (3) escaping immune surveillance. Gas6 and Axl are also expressed by a number of host cells, including immune cells. Axl-expressing cDCs mediate cytokine secretions, and neoplastic cells upregulate Gas6 expression by the immune cells in the TME. Hence, both neoplastic and host cells found in the TME utilize the Gas6/Axl signaling pathway to promote aggressive tumor phenotypes.

Although this present review focuses on the role of the Gas6/Axl signaling pathway in the TIME, the other TAM family members Tyro3 and MerTK also are expressed by numerous neoplastic and host cells. For example, MerTK expression is elevated in immunosuppressive, M2-like macrophages compared to M1-like macrophages \[[@B93-cancers-12-01850],[@B94-cancers-12-01850],[@B95-cancers-12-01850]\]. This macrophage polarization is, in part, potentiated by a Gas6-mediated mechanism \[[@B96-cancers-12-01850]\]. Hence, the various TAM ligands and receptors may have overlapping roles that could further promote the immunosuppressive TIME. Our understanding of the Tyro3 and MerTK pathways will surely evolve as will the story of the Gas6/Axl signaling pathway in the TIME.

Given that Gas6 and Axl are expressed on both neoplastic and host cells, targeting this pathway presents a novel strategy to impair multiple stages of cancer development, progression, and metastasis. A number of Axl inhibitors have been developed and studied in preclinical and clinical settings for various cancer types \[[@B97-cancers-12-01850]\]. As preclinical evidence pointing to the possible immunomodulatory roles of the Gas6/Axl pathway has evolved, clinical trials, such as the combination of the Axl inhibitor bemcentinib with pembrolizumab, have been initiated (ClinicalTrials.gov Identifier: NCT03654833, NCT03184558, NCT03184571). Indeed, understanding the Gas6/Axl signaling in the TIME undoubtedly will lead to the design of future therapeutic targeting strategies that may ultimately improve treatment outcomes.
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![Structures and expression profiles of Gas6 and Axl. (**A**) The growth arrest specific 6 (Gas6) protein belongs in the family of vitamin K-dependent proteins. Gas6 consists of a gamma-carboxyglutamic acid (Gla) domain, four epidermal growth factor (EGF)-like domains, and two laminin G (LG)-like domains. Axl belongs in the Tyro3, Axl, MerTK (TAM) subfamily of the receptor tyrosine kinases. Axl consists of immunoglobulin-like (IgL) domains, two fibronectin domains, and a kinase domain. (**B**) Axl is expressed in a number of tumor types. The Gas6/Axl signaling promotes tumor cell survival, proliferation, migration, invasion, angiogenesis, therapeutic resistance, and immune evasion. (**C**) Gas6 and Axl are expressed by host stromal cells, including endothelial cells, fibroblasts, osteoblasts, monocytes, platelets, natural killer (NK) cells, dendritic cells (DCs), and macrophages.](cancers-12-01850-g001){#cancers-12-01850-f001}

![The Gas6/Axl signaling promotes the immunosuppressive tumor microenvironment. Axl signaling modulates surface level expression of major histocompatibility complex I (MHC-I) and programmed death ligand-1 (PD-L1) on neoplastic cells. The Gas6/Axl signaling also promotes secretion of immunosuppressive chemokines, including CCL3-5, G-CSF, IL-3, IL-4, IL-6, IL-12_p70, TGFβ, and TNFα. In the context of the tumor immune microenvironment, the Gas6/Axl signaling promotes infiltration of macrophages, monocytes, and myeloid-derived suppressor cells (MDSCs), but decreases infiltration of CD4^+^ and CD8^+^ T-cells, and conventional dendritic cells in the tumor.](cancers-12-01850-g002){#cancers-12-01850-f002}

cancers-12-01850-t001_Table 1

###### 

Axl Signaling Modulates Secretion of Cytokines.

  Changes in Cytokine Secretion upon Axl Inhibition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------
  **Colony stimulating factors**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                          CSF-1 \[[@B84-cancers-12-01850]\], CSF-2 \[[@B77-cancers-12-01850]\] ^b^, CSF-3 \[[@B77-cancers-12-01850],[@B84-cancers-12-01850]\] ^b,c^                                                                                                                                                                                                                                                                                                                               CSF-2 \[[@B84-cancers-12-01850]\] ^c^
  **Interleukin family**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  IL-12p40 \[[@B76-cancers-12-01850]\] ^a^                                                                                IL-1a \[[@B77-cancers-12-01850]\] ^b^, IL-3-5 \[[@B84-cancers-12-01850]\] ^c^, IL-6 \[[@B77-cancers-12-01850]\] ^b^, IL-9 \[[@B84-cancers-12-01850]\] ^c^, IL-10 \[[@B76-cancers-12-01850]\] ^a^, IL-12p40 \[[@B84-cancers-12-01850]\] ^c^, IL-12p70 \[[@B84-cancers-12-01850]\] ^c^, IL-13 \[[@B84-cancers-12-01850]\] ^c^, IL-15 \[[@B84-cancers-12-01850]\] ^c^, IL-17 \[[@B84-cancers-12-01850]\] ^c^                                                               IL-1a \[[@B84-cancers-12-01850]\] ^c^, IL-2 \[[@B84-cancers-12-01850]\] ^c^, IL-10 \[[@B84-cancers-12-01850]\] ^c^, LIF \[[@B84-cancers-12-01850]\] ^c^
  **Chemokine family**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  CXCL9 \[[@B76-cancers-12-01850]\] ^a^, CXCL10 \[[@B76-cancers-12-01850]\] ^a^, CXCL11 \[[@B76-cancers-12-01850]\] ^a^   CCL-2 \[[@B76-cancers-12-01850],[@B84-cancers-12-01850]\] ^a,c^, CCL-3 \[[@B76-cancers-12-01850],[@B77-cancers-12-01850],[@B84-cancers-12-01850]\] ^a,b,c^, CCL-4 \[[@B76-cancers-12-01850],[@B77-cancers-12-01850],[@B84-cancers-12-01850]\] ^a,b,c^, CCL-5 \[[@B76-cancers-12-01850],[@B77-cancers-12-01850],[@B84-cancers-12-01850]\] ^a,b,c^, CXCL1 \[[@B84-cancers-12-01850]\] ^c^, CXCL2 \[[@B84-cancers-12-01850]\] ^c^, CXCL5 \[[@B84-cancers-12-01850]\] ^c^   CXCL12 \[[@B76-cancers-12-01850]\] ^a^
  **Other family of cytokines**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  INF𝛾 \[[@B76-cancers-12-01850]\] ^a^                                                                                    TGF𝛽 \[[@B76-cancers-12-01850]\] ^a^, TNF𝛼 \[[@B77-cancers-12-01850],[@B84-cancers-12-01850]\] ^b,c^                                                                                                                                                                                                                                                                                                                                                                    INF𝛾 \[[@B84-cancers-12-01850]\] ^c^

Tumor types: ^a^ Ovarian and breast cancer models (ID8 and 4T1); ^b^ breast cancer cell line (Py8119); ^c^ pancreatic adenocarcinoma model, Kras^LSL-G12D^; Cdkn2a^fl/fl^; Ptf1a^Cre/+^ (KIC).

cancers-12-01850-t002_Table 2

###### 

Effects of Axl Inhibition on Tumor Infiltrating Immune Cells.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumor Infiltrating Immune\                                                   Identification Method   Effects of Axl Inhibition: Increased, Decreased, No Difference \[Ref\]
  Cell Markers                                                                                         
  ---------------------------------------------------------------------------- ----------------------- -------------------------------------------------------------------------------
  Leukocytes (CD45^+^)                                                         FCM                     Increased \[[@B76-cancers-12-01850]\] ^a^ \[[@B77-cancers-12-01850]\] ^b^

  **T-cell subtypes**                                                                                  

  CD4^+^ T-cells\                                                              \                       \
  (CD3^+^ CD4^+^ FoxP3^-^)\                                                    FCM\                    Increased \[[@B76-cancers-12-01850]\] ^a^\
  (CD3^+^ CD4^+^)                                                              FCM                     No difference \[[@B77-cancers-12-01850]\] ^b^

  CD8^+^ T-cells (CD3^+^ CD8^+^)                                               FCM                     Increased \[[@B76-cancers-12-01850]\] ^a^ \[[@B77-cancers-12-01850]\] ^b^

  Tregs (CD3^+^ CD4^+^ FoxP3^+^)                                               FCM                     No difference \[[@B76-cancers-12-01850]\] ^a^ \[[@B77-cancers-12-01850]\] ^b^

  **Myeloid-lineage cells**                                                                            

  Conventional dendritic cells\                                                FCM                     Increased \[[@B76-cancers-12-01850]\] ^a^ \[[@B77-cancers-12-01850]\] ^b^
  (CD11b^+^ CD11c^+^ MHC-II^+^)                                                                        

  Monocytes/Macrophages\                                                       FCM                     Decreased \[[@B76-cancers-12-01850]\] ^a^
  (CD11b^+^ F4/80^+^ Ly6G^-^)                                                                          

  TAM (CD11b^+^ Ly-6G^-^ Ly-6C^-^ F4/80^+^ CD11c^+^ MHC-II^+^)                 FCM                     Decreased \[[@B84-cancers-12-01850]\] ^c^

  Arg^+^ TAM (CD11b^+^ Ly-6G^-^ Ly-6C^-^ F4/80^+^ CD11c^+^ MHC-II^+^ Arg^+^)   FCM                     Decreased \[[@B84-cancers-12-01850]\] ^c^

  Arg^+^ Macrophages (F4/80^+^ Arg^+^)                                         IF                      Decreased \[[@B84-cancers-12-01850]\] ^c^

  Granulocytes (CD11b^+^ F4/80^-^ Ly-6G^+^)                                    FCM                     Decreased \[[@B76-cancers-12-01850]\] ^a^

  M-MDSC (CD11b^+^ Ly-6G^-^ Ly-6C^+^)                                          FCM                     Decreased \[[@B84-cancers-12-01850]\] ^c^

  PD-L1^+^ M-MDSC\                                                             FCM                     Decreased \[[@B84-cancers-12-01850]\] ^c^
  (CD11b^+^ Ly-6G^-^ Ly-6C^+^ PD-L1^+^)                                                                

  PMN-MDSC (CD11b^+^ Ly-6G^+^ Ly-6C^+^)                                        FCM                     No difference \[[@B84-cancers-12-01850]\] ^c^

  PD-L1 PMN-MDSC\                                                              FCM                     No difference \[[@B84-cancers-12-01850]\] ^c^
  (CD11b^+^ Ly-6G^+^ Ly-6C^+^ PD-L1^+^)                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Guo and colleagues used murine ovarian and breast cancer models (ID8 and 4T1), and treated mice with 100 mg/kg bemcentinib (5 consecutive days/week). ^b^ Aguilera and colleagues used an Axl knockout murine breast cancer cell line (Py8119). The Axl knockout cell line was inoculated into wild-type syngeneic C57Bl/6 mice. ^c^ Ludwig and colleagues used murine pancreatic adenocarcinoma models (KPC-M09, Pan02, and KIC), and treated mice with 50 mg/kg bemcentinib twice daily. Abbreviations: Tregs---regulatory T-cells, TAM---tumor associated macrophages, M-MDSC---monocytic myeloid derived suppressor cell, PMN-MDSC---polymorphonuclear myeloid derived suppressor cell, FCM---Flow cytometry, IF---immunofluorescence.
